Arch Oncology
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2000 Sierra Point Pkwy Fl 700, Brisbane,...Phone Number
(415) 671-4035Website
www.archoncology.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Arch Oncology
Arch Oncology, Inc. was founded in 2006 out of Brisbane, California, they are a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class biologic therapies for the treatment of patients with solid tumors and hematologic malignancies. AO-176, the Company's next-generation anti-CD47 antibody, is highly differentiated, with the potential for an improved safety and efficacy profile relative to other agents in this class. AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with hematologic malignancies, both as monotherapy and in combination with standard therapies. In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer.Explore more
Arch Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arch Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Arch Oncology
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Arch Oncology recently announced quarterly report
Click to see if Arch Oncology had a recent Job posting/layoffs
Check if Arch Oncology has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Arch Oncology has new funding data
Check out if Arch Oncology is spiking on competitors!
Product Launch: Get notified when Arch Oncology launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Arch Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Arch Oncology
Compare insights from companies similar to Arch Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arch Oncology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Arch Oncology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Arch Oncology.
Arch Oncology financials insights
Gather financial insights about Arch Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$86M
2019
Series B
$50M
2020
Debt
$350K
2021
Series C
$105M
Arch Oncology Tech Stack
A closer look at the technologies used by Arch Oncology
Most Recent Scoops
Layoffs
Pain Point
Pain Point, Layoffs
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Arch Oncology has announced that Ronald Krasnow, Chief Operating Officer, has left the company to join T-Knife Therapeutics as General Counsel.
Executive Move
Executive Moves
Arch Oncology News & Media
Arch Oncology Raises $105M in Series C Financing
Arch Oncology, Inc., a Brisbane, Calif. and St. Louis, MO-based clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, closed a $105m Series C financing. The round, announced in April 2020, was co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3×5 Partners, who were joined by new investors […] The post Arch Oncology Raises $105M in Series C Financing appeared first on FinSMEs.Arch Oncology Secures $105 Million Series C Financing
– Proceeds to support clinical progress of differentiated anti-CD47 candidate AO-176 for patients with solid tumors and hematologic malignancies – –...Arch Oncology to Participate in Upcoming Conferences
BRISBANE, Calif. and ST. LOUIS, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the company’s participation at upcoming healthcare investor conferences:Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors
With Encouraging Safety and Anti-tumor Activity for AO-176 Monotherapy in Phase 1 Trial, Advancing AO-176 in Combination with Anti-PD-1 With Encouraging Safety and Anti-tumor Activity for AO-176 Monotherapy in Phase 1 Trial, Advancing AO-176 in Combination with Anti-PD-1
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Arch Oncology
Sign Up For FreeTo access detailed company insights
Arch Oncology, Inc. was founded in 2006 out of Brisbane, California, they are a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class biologic therapies for the treatment of patients with solid tumors and hematologic malignancies. AO-176, the Company's next-generation anti-CD47 an... Read More
